|
2025
|
Invention
|
Composition for use in reducing the risk of recurrent acute urinary retention. The present invent... |
|
2024
|
Invention
|
Teverelix-tfa in a dosage regime for use in the treatment of prostate cancer |
|
|
Invention
|
Teverelix-tfa in a dosage regime for use in the treatment of prostate cancer. The present inventi... |
|
2023
|
Invention
|
Lyophilization process and a teverelix-tfa lyophilizate obtained thereby.
The present invention ... |
|
|
Invention
|
Reconstitutable teverelix-tfa composition. The present invention relates to a reconstitutable tev... |
|
2022
|
Invention
|
Teverelix-tfa composition. Provided is a teverelix-TFA composition having a molar ratio of tevere... |
|
2019
|
Invention
|
Lyophilization process and a teverelix-tfa lyophilizate obtained thereby. The present invention r... |
|
|
Invention
|
Teverelix-tfa composition. A teverelix-TFA composition having a molar ratio of teverelix to trifl... |
|
|
Invention
|
Teverelix-tfa composition. The present invention relates to a teverelix-TFA composition having a ... |
|
|
Invention
|
A lyophilization process and a teverelix-tfa lyophilizate obtained thereby. The present invention... |
|
|
Invention
|
A reconstitutable teverelix-tfa composition. The present invention relates to a reconstitutable t... |
|
2018
|
Invention
|
Composition for treating acute urinary retention.
The present invention provides a composition f... |
|
|
Invention
|
Composition for treating acute urinary retention. The present invention provides a composition fo... |
|
|
Invention
|
A composition comprising at least one gnrh antagonist.
The present invention relates to a compos... |
|
|
Invention
|
A composition comprising at least one gnrh antagonist. The present invention relates to a composi... |
|
|
Invention
|
Combination administration of gnrh antagonists.
Disclosed herein are methods of administering to... |
